Sauer SM, Mitnick CD, Khan UT, Hewison CCH, Bastard M, et al.
2024-01-25 • Clinical Infectious Diseases
2024-01-25 • Clinical Infectious Diseases
BACKGROUND Quantification of recurrence risk following successful treatment is crucial to evaluating regimens for multidrug- or rifampicin-resistant (MDR/RR) tuberculosis (TB). Howev...
Zeng C, Mitnick CD, Hewison CCH, Bastard M, Khan PY, et al.
2023-01-01 • International Journal of Tuberculosis and Lung Disease
2023-01-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND The WHO provides standardized outcome definitions for rifampicin-resistant (RR) and multidrug-resistant (MDR) TB. However, operationalizing these definitions can be challe...